Akari Therapeutics Plc (NASDAQ:AKTX) shares are ripping higher after the company released preclinical data showing AKTX‑101 produced synergistic activity alongside KRAS inhibition in KRAS-mutated pancreatic cancer models.
Akari Therapeutics stock is showing exceptional strength. What’s fueling AKTX momentum?
Something went wrong.
Synergy Observed In KRAS‑Mutant Pancreatic Cancer Models
Akari reported that in pancreatic cancer models driven by KRAS G12D and KRAS G12C mutations, combining AKTX‑101, its ADC powered by the PH1 RNA spliceosome‑modulating payload, with adagrasib, a KRAS inhibitor, produced strong synergistic cell‑killing activity. In other words, when AKTX-101 was combined with adagrasib, a KRAS inhibitor, the two agents worked together more effectively than either alone in these KRAS‑mutant cell lines.
